BioMarin, Genzyme Restructure Aldurazyme Joint Venture
This article was originally published in The Pink Sheet Daily
Executive Summary
BioMarin to receive tiered payments based on worldwide net sales of mucopolysaccharidosis I drug under revised deal.
You may also be interested in...
Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
FDA Clears First Drug To Treat Phenylketonuria
BioMarin estimates Kuvan revenue of $57,000 per patient per year.